GAS5 and neoplasm: It is found that m6A modification in GAS5, a tumor suppresser, would lead to GAS5 degradation via binding to m6A reader YTHDF3 in colorectal cancer (CRC), which further results in the decreased expression of YAP (Ni et al., 2019).